Drugs / Pegvorhyaluronidase Alfa
Pegvorhyaluronidase Alfa
English name null
Trials 19 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03481920 | Jan 2018 → Jan 2019 | pancreatic ductal adenocarcinoma | PH Research, S.L. | Terminated | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT03267940 | Oct 2017 → Nov 2019 | gallbladder adenocarcinoma, intrahepatic cholangiocarcinoma | Halozyme Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT02563548 | Oct 2015 → Mar 2019 | gastric adenocarcinoma, non-small cell lung carcinoma | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02346370 | Feb 2015 → Aug 2016 | non-small cell lung carcinoma | Halozyme Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT01170897 | Jul 2010 → Oct 2013 | neoplasm | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00834704 | Feb 2009 → Jun 2012 | cancer | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03193190 | Jul 2017 → Feb 2025 | pancreatic adenocarcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT01959139 | Jan 2014 → Apr 2019 | pancreatic adenocarcinoma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 1/2 | NCT01453153 | Sep 2011 → Feb 2014 | pancreas disorder | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT04058964 | Feb 2020 → Oct 2022 | pancreatic adenocarcinoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT04134468 | Jan 2020 → Feb 2021 | pancreatic ductal adenocarcinoma | Abramson Cancer Center at Penn Medicine | Withdrawn | No outcome recorded |
| Phase 2 | NCT04045730 | Nov → Dec 2019 | pancreatic adenocarcinoma | Yale University | Withdrawn | No outcome recorded |
| Phase 2 | NCT03979066 | Nov 2019 | pancreatic ductal adenocarcinoma | Gulam Manji | Terminated | No outcome recorded |
| Phase 2 | NCT03634332 | May 2019 → Oct 2020 | pancreatic ductal adenocarcinoma | Pancreatic Cancer Research Team | Unknown | No outcome recorded |
| Phase 2 | NCT02487277 | Jul 2015 → May 2018 | pancreatic adenocarcinoma | Andrew Ko | Terminated | No outcome recorded |
| Phase 2 | NCT01839487 | May 2013 → May 2018 | pancreatic ductal adenocarcinoma | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02715804 | Mar 2016 → Nov 2019 | pancreatic ductal adenocarcinoma | Halozyme Therapeutics | Terminated | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT02921022 | Oct 2016 → Oct 2026 expected | pancreatic ductal adenocarcinoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| — | NCT02241187 | Sep 2014 → Sep 2016 | pancreatic adenocarcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegvorhyaluronidase Alfa | “The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic...” NCT04045730 ↗4“Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non-small cell lung cancer.” PMID 33982408 ↗ Jul 2021 “pegvorhyaluronidase alfa (PEGPH20) degrades HA” PMID 29232172 ↗ Dec 2017 “PEGPH20 (Pegvorhyaluronidase Alfa)” NCT04058964 ↗ |
| Known as | PEGPH20 | “The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic...” NCT04045730 ↗15“PEGylated Recombinant Human Hyaluronidase (PEGPH20)” NCT02715804 ↗ |
| Known as | Pegvorhialuronidasa alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989976 ↗ |
| Known as | PEGylated Recombinant Human Hyaluronidase | “A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With...” NCT03267940 ↗3“A study of PEGylated recombinant human hyaluronidase (PEGPH20) administered on a twice weekly schedule for 28 days followed by a weekly dosing schedule in patients with...” NCT01170897 ↗ “PEGylated Recombinant Human Hyaluronidase (PEGPH20)” NCT03481920 ↗ “PEGylated Recombinant Human Hyaluronidase (PEGPH20)” NCT02715804 ↗ |
| Known as | Pegylated Recombinant Human Hyaluronidase PH20 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04058964 ↗ |
| Known as | PVHA | “pegvorhyaluronidase alfa (PVHA; PEGPH20) on the plasma pharmacokinetics (PKs) and safety of docetaxel” PMID 33982408 ↗ Jul 2021 |
| Modality | Protein / enzyme biologic | “PEGylated recombinant human hyaluronidase” NCT00834704 ↗ |
| Route | Intravenous | “Given intravenously” NCT00834704 ↗ |